QualityStocksNewsBreaks Archives - Page 369 of 1274

MondayDec 06, 2021 12:57 pm

QualityStocksNewsBreaks – PlantX Life Inc. (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) Announces Launch of PlantX UK

PlantX Life (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) today announced the expansion of its e-commerce platform to the United Kingdom. Per the update, PlantX UK will launch under a new domain, www.PlantX.UK, and offer a similar experience as PlantX.ca and PlantX.com provide in Canada and the United States, respectively. The new platform will feature an extensive assortment of plant-based goods, an abundant indoor plant selection and a variety of educational resources, including blogs and recipes. In addition, www.PlantX.UK will complement Bloomboxclub Limited, PlantX’s e-commerce business that sells and delivers indoor plants across the United Kingdom and Germany. “PlantX plans to introduce a wide selection…

MondayDec 06, 2021 12:41 pm

QualityStocksNewsBreaks – Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Focused on Efforts to Support ESG Priorities

Energy Fuels (NYSE American: UUUU) (TSX: EFR) places a high priority in the production of raw materials that support global clean-energy efforts. This comes as the world is becoming more focused on and committed to clean energy and sustainability, with companies in every sector recognizing the importance of advancing ESG (environmental, sustainability and governance) priorities. “With that as a backdrop, Energy Fuels does much more than just produce uranium, which is the fuel for nuclear energy, producing 50% of all clean, carbon-free electricity in the U.S.,” a recent article reads. In addition to producing uranium, UUUU began operations to recover…

MondayDec 06, 2021 12:24 pm

QualityStocksNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Patent Application Covering Multiple Families of Psilocin Analogs

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced it has filed a full patent application covering multiple families of psilocin analogs. According to the update, the application includes solutions to directly address further precision in delivery control and shelf stabilization of psilocin, psilocybin’s active metabolite, both of which are critical for use in the medical setting. “The goal of creating these improved second-generation compounds is to enable safer, more effective treatments for patients along with improved management of dosage and drug behavior…

MondayDec 06, 2021 11:43 am

QualityStocksNewsBreaks – FuelPositive Corporation (TSX.V: NHHH) (OTCQB: NHHHF) Offering Much-Needed Resolution to Challenges Plaguing Climate Change Talks

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) provides a viable and actionable solution for countries seeking to eliminate fossil fuels. The company also offers a much-needed resolution to challenges that are plaguing climate change talks, from the Group of 20 (“G20”) Summit to the United Nations Climate Change Conference (“COP26”). The G20 Summit, for example, was marked by a reluctance by countries in attendance to make firm commitments on issues such as net-zero carbon emissions and phasing out coal and fossil fuels. This is despite the inevitable and indisputable catastrophe linked to unchecked climate change. It emerged that fossil fuels appeared to…

MondayDec 06, 2021 10:30 am

QualityStocksNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Announces 2022 Revenue Guidance, to Host Dec. 14 Webinar

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products, today announced 2022 revenue guidance of $35-45 million. According to the update, this incorporates revenue contributions from the company’s various operating divisions, including recently acquired Vessel Brand and wholesale cannabis revenues from Cosechemos. In addition, Flora announced that it will hold a webinar at 4:30 p.m. ET on Tuesday, Dec. 14, 2021. During the webinar, Flora CEO Luis Merchan will provide an update on the operational performance for 2021 to date, additional comments on the financial guidance for 2022, and hold a brief question-and-answer session. Interested parties…

FridayDec 03, 2021 1:02 pm

QualityStocksNewsBreaks – Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) on Course to Making Actionable Health Information More Accessible

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) is increasing access to the innovations of its walk-in pharmacy diagnostic technology. Recently, the company expanded from key cities in Canada’s eastern locales to sites on the western seaboard, where it hopes to diversify the profile of patients using its service. “The addition of five British Columbia outlets through Avricore’s pilot partnership with nationwide pharmaceutical chain Shoppers Drug Mart is expected to serve as an early booster stage for the company’s plans to serve 600 locations by the end of 2023,” reads a recent article. In an earlier news release, CEO Hector Bremner commented:…

FridayDec 03, 2021 12:30 pm

QualityStocksNewsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Announces Beginning of Validation Process for Class 2 EV Cargo Vans

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has started the initial validation testing of its exclusive Class 2 EV cargo van. The testing is taking place at Mullen’s Advanced Manufacturing and Engineering Center (“AMEC”), which is located in Tunica, Mississippi. Based on a 144-inch wheelbase, Mullen’s Class 2 EV cargo van features a 78.8-kWh battery pack as well as rear-wheel drive and a modular 460-cubic-foot cargo area. In addition, the vehicle offers a range of more than 200 miles and a maximum payload of 3,296 pounds. “Our Class 2 EV cargo van initial validation testing has begun…

FridayDec 03, 2021 12:18 pm

QualityStocksNewsBreaks – Sugarmade Inc. (SGMD) Expanding End-Market Access in Growing California Cannabis Delivery Sector

Sugarmade (OTC: SGMD), an innovator in the dynamic California cannabis sector, is focused on expanding its end-market access as a central player in the growing space. This comes as more consumers around the world become aware of the potential benefits of cannabis. As a result, the market is projected to see significant growth, with a new Quince Market Insights report estimating that the global cannabis market will grow at a CAGR of 27.0% from 2021 to 2030 (https://ibn.fm/3WgpH) (https://nnw.fm/ESCca) (https://cnw.fm/pZlDm). “The growth factors identified in the market are the proven medicinal effects and legalization of cannabis, developments in intellectual property…

FridayDec 03, 2021 11:43 am

QualityStocksNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), Announces Participation in December 2021 Conferences

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, will be featured in several upcoming conferences. The company announced that president and CEO Kelsey Ramsden has been invited to present in four virtual conferences scheduled in December. Those conferences include the H.C. Wainwright's second annual Psychedelics Conference, the Psychedelics Now Virtual Conference, the #CanndoraConnect: Women in Psychedelics Conference, and the Life Sciences Investor Forum. The H.C. Wainwright Psychedelics Conference is scheduled for Dec. 6, 2021; Ramsden’s presentation will begin at 7 a.m. The Psychedelics Now Virtual Conference will be held…

FridayDec 03, 2021 11:27 am

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at 2nd Annual H.C. Wainwright Psychedelics Conference

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it will present at the Second Annual H.C. Wainwright Psychedelics Conference. The event is slated to be held virtually on Dec. 6, 2021. Tryp’s chairman and CEO Greg McKee will provide an overview of the business and its pipeline, including the upcoming phase 2a clinical trials in fibromyalgia, phantom limb pain, binge eating disorder and other indications. McKee's presentation will be available on-demand through the H.C. Wainwright conference portal beginning at 7:00 a.m. ET. on Monday, Dec.…

Site Search

Company Search

Category: QualityStocksNewsBreaks